Dyne Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
Dyne Therapeutics, Inc. (DYN) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 3.71% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2026-07-29
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2026-03-31 was 3.71%, a 7.94% decline year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2025-03-31 was 4.03%, a 1.26% increase year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2024-03-31 was 3.98%, a 16.37% increase year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2023-03-31 was 3.42%, a 132.65% increase year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2025 was 3.65%, a 5.49% increase from fiscal 2024.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2024 was 3.46%, a 1.17% increase from fiscal 2023.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2023 was 3.42%, a 132.65% increase from fiscal 2022.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2022 was 1.47%, a 79.27% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month |
|---|---|---|---|---|
| 2026-06-30 | 3.71% 10-Q · filed 2026-07-29 | |||
| 2026-03-31 | 3.71% 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | 3.65% 10-K · filed 2026-03-02 | |||
| 2025-09-30 | 3.71% 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | 3.91% 10-Q · filed 2026-07-29 | |||
| 2025-03-31 | 4.03% 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | 3.46% 10-K · filed 2026-03-02 | |||
| 2024-09-30 | 3.46% 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | 3.98% 10-Q · filed 2025-07-28 | |||
| 2024-03-31 | 3.98% 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | 3.42% 10-K · filed 2025-02-27 | |||
| 2023-09-30 | 3.42% 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | 3.42% 10-Q · filed 2024-08-12 | |||
| 2023-03-31 | 3.42% 10-Q · filed 2024-05-02 | |||
| 2022-12-31 | 1.47% 10-K · filed 2024-03-05 | |||
| 2022-09-30 | 1.47% 10-Q · filed 2023-10-30 | |||
| 2022-06-30 | 1.47% 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | 1.47% 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | 0.82% 10-K · filed 2023-03-02 | |||
| 2021-09-30 | 0.82% 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | 0.88% 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | 0.88% 10-Q · filed 2022-05-02 | |||
| 2020-12-31 | 0.31% 10-K · filed 2022-03-10 | |||
| 2020-09-30 | 0.31% 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | 0.45% 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | 0.79% 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | 1.46% 10-K · filed 2021-03-04 | |||
| 2019-09-30 | 1.46% 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |